UTHR - UNITED THERAPEUTICS Corp

QQQ $ 441.71 $ 1.04 (0.24 %)

DIA $ 395.04 $ 1.18 (0.3 %)

SPY $ 520.76 $ 0.67 (0.13 %)

TLT $ 90.14 $ -0.51 (-0.56 %)

GLD $ 218.73 $ 1.76 (0.81 %)

Previous Close

$ 264.27

Open

$ 266.42

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 264.02 - $ 269.55

52 Week Range

$ 204.44 - $ 269.81

Volume

391,702

Average Volume

Market Cap

13.13B

Beta (5Y Monthly)

$ 0.50

PE Ratio (TTM)

$ 12.50

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-01-2024	03-31-2024	10-Q
2	02-21-2024	12-31-2023	10-K
3	11-01-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	02-22-2023	12-31-2022	10-K
7	11-02-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-24-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	08-04-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	02-24-2021	12-31-2020	10-K
15	10-28-2020	09-30-2020	10-Q
16	07-29-2020	06-30-2020	10-Q
17	04-29-2020	03-31-2020	10-Q
18	02-26-2020	12-31-2019	10-K
19	10-30-2019	09-30-2019	10-Q
20	07-31-2019	06-30-2019	10-Q
21	05-01-2019	03-31-2019	10-Q
22	02-27-2019	12-31-2018	10-K
23	10-31-2018	09-30-2018	10-Q
24	08-01-2018	06-30-2018	10-Q
25	05-02-2018	03-31-2018	10-Q
26	02-21-2018	12-31-2017	10-K
27	10-25-2017	09-30-2017	10-Q
28	07-27-2017	06-30-2017	10-Q
29	04-26-2017	03-31-2017	10-Q
30	02-22-2017	12-31-2016	10-K
31	10-27-2016	09-30-2016	10-Q
32	07-28-2016	06-30-2016	10-Q
33	04-28-2016	03-31-2016	10-Q
34	02-25-2016	12-31-2015	10-K
35	10-27-2015	09-30-2015	10-Q
36	07-28-2015	06-30-2015	10-Q
37	04-28-2015	03-31-2015	10-Q
38	02-24-2015	12-31-2014	10-K
39	10-28-2014	09-30-2014	10-Q
40	07-29-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Goldman Sachs Maintains Neutral on United ...
05/03/2024 16:03:20

Goldman Sachs analyst Chris Shibutani maintains United Therapeutics (NASDAQ:UTHR) with a Neutral and raises the price target...

The Latest Analyst Ratings For United Ther...
05/02/2024 13:00:40

Oppenheimer Maintains Outperform on United...
05/02/2024 13:00:08

Oppenheimer analyst Hartaj Singh maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target f...

HC Wainwright & Co. Reiterates Buy on Unit...
05/02/2024 10:57:03

HC Wainwright & Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:UTHR) with a Buy and maintains $300 price...

lung-disease-focused-united-therapeutics-says-it-is-a-compelling-investment-opportunity

Lung Disease-Focused United Therapeutics S...
05/01/2024 18:35:39

United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyv...

powell-industries-posts-upbeat-results-joins-a10-networks-garmin-dupont-and-other-big-stocks-moving-higher-on-wednesday

Powell Industries Posts Upbeat Results, Jo...
05/01/2024 14:27:48

United Therapeutics Q1 2024 GAAP EPS $6.17...
05/01/2024 10:32:39

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $...

United Therapeutics Announces Xenothymokid...
04/24/2024 13:04:43

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transp...

Liquidia Says Judge Andrews Has Set Aside ...
04/01/2024 10:09:19

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
03/26/2024 21:32:33

United Therapeutics Announces $1B Accelera...
03/25/2024 11:02:00

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has a...

United Therapeutics Filed Motion In U.S. D...
02/27/2024 11:18:25

Liquidia’s investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hyperte...

Beyond The Numbers: 4 Analysts Discuss Uni...
02/22/2024 14:00:39

Wedbush Reiterates Outperform on United Th...
02/22/2024 13:22:02

Wedbush analyst Liana Moussatos reiterates United Therapeutics (NASDAQ:UTHR) with a Outperform and maintains $308 price target.

HC Wainwright & Co. Reiterates Buy on Unit...
02/22/2024 11:48:10

HC Wainwright & Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:UTHR) with a Buy and maintains $300 price...

united-therapeutics-challenges-fda-over-liquidias-drug-approval-process-clocks-strong-q4-earnings

United Therapeutics' Challenges FDA Over L...
02/21/2024 18:17:03

Legal battle unfolds as United Therapeutics challenges FDA's handling of Liquidia's drug approval process. Explore the ...

United Therapeutics Q4 GAAP EPS $4.36 Beat...
02/21/2024 11:01:20

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $4.36 per share which beat the analyst consensus estimate of $...

United Therapeutics Has Commenced Litigati...
02/21/2024 10:59:20

Earnings Scheduled For February 21, 2024
02/21/2024 10:09:04

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on...

Earnings Outlook For United Therapeutics
02/20/2024 19:01:19